List of Excipients in Branded Drug QUILLIVANT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
NextWave Pharmaceuticals Inc	QUILLIVANT	methylphenidate hydrochloride	24478-190	ANHYDROUS CITRIC ACID
NextWave Pharmaceuticals Inc	QUILLIVANT	methylphenidate hydrochloride	24478-190	ANHYDROUS TRISODIUM CITRATE
NextWave Pharmaceuticals Inc	QUILLIVANT	methylphenidate hydrochloride	24478-190	POLOXAMER 188

Quillivant XR Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

Quillivant XR is an extended-release oral suspension of methylphenidate hydrochloride developed and marketed by Tris Pharma for attention-deficit/hyperactivity disorder. Its commercial differentiation depends on liquid delivery, taste acceptance, dose flexibility, and extended-release microparticle technology rather than on the active ingredient alone. The strongest excipient opportunities are sugar reduction, improved palatability, lower preservative burden, longer in-use stability, and adaptation for pediatric and adolescent subgroups with swallowing, sensory, or dietary restrictions.

What is Quillivant XR and how does its formulation work?

Quillivant XR contains methylphenidate hydrochloride at a concentration of 25 mg per 5 mL after reconstitution. It is supplied as a powder for oral suspension and is administered once daily in the morning. The product uses extended-release methylphenidate particles suspended in an aqueous vehicle. The labeled dose range is generally 20 mg to 60 mg once daily for patients age six years and older, with titration based on clinical response and tolerability. [1]

The dosage form addresses several limitations of solid oral stimulants:

• Patients who cannot swallow tablets or capsules can receive a liquid dose.
• Prescribers can titrate by volume in 0.5 mL increments.
• The formulation provides once-daily exposure rather than repeated immediate-release dosing.
• Caregivers can administer the product using a supplied oral dosing syringe.

The formulation is commercially difficult to replicate because the release profile depends on particle engineering, coating technology, suspension rheology, taste masking, redispersibility, and dose uniformity.

What excipients are used in Quillivant XR?

The FDA prescribing information identifies the principal inactive ingredients as sucrose, microcrystalline cellulose and carboxymethylcellulose sodium, sodium benzoate, polysorbate 80, citric acid, sodium citrate, sucralose, and flavoring. [1]

Excipient or excipient system	Primary function	Commercial relevance
Sucrose	Sweetness, bulk, mouthfeel	Supports pediatric palatability but creates sugar-content and dental-health concerns
Microcrystalline cellulose	Suspending and structuring aid	Helps maintain particle distribution
Carboxymethylcellulose sodium	Viscosity and suspension stabilization	Supports dose uniformity after shaking
Sodium benzoate	Preservative	Controls microbial growth in the aqueous product
Polysorbate 80	Wetting and dispersion aid	Supports uniform wetting of hydrophobic drug particles
Citric acid and sodium citrate	Buffering and pH control	Stabilize the formulation and influence taste
Sucralose	High-intensity sweetener	Improves taste without relying solely on sucrose
Flavoring	Taste masking	Important for adherence in pediatric patients

The excipient system has two linked objectives: maintaining a physically stable suspension and making the product acceptable to children. A change that improves taste can impair viscosity, wetting, preservative performance, or release characteristics.

What excipient technologies are commercially important for Quillivant XR?

Suspension stabilization

Microcrystalline cellulose and carboxymethylcellulose sodium create a structured vehicle that helps keep extended-release particles suspended. The target is not maximum viscosity. Excessive viscosity can make the product difficult to pour, difficult to withdraw through a syringe, and inconsistent at the beginning and end of the bottle.

Potential development areas include:

• Cellulose-polymer blends with improved shear-thinning behavior
• Low-viscosity suspending systems with stronger particle settling control
• Natural or semi-synthetic hydrocolloid combinations
• Structured vehicles that redisperse rapidly with limited shaking
• Excipient systems compatible with high drug loading

The highest-value opportunity is a vehicle that maintains dose uniformity while reducing the force required to shake and draw the dose.

Taste masking

Methylphenidate can produce bitter, medicinal, or lingering taste sensations. Quillivant XR already uses sucrose, sucralose, and flavoring, but taste performance remains a central commercial variable in pediatric stimulant treatment.

A differentiated taste-masking program could use:

• Ion-pairing or complexation of methylphenidate
• Polymer coating of drug particles
• Lipid or lipid-polymer barriers
• pH-triggered release in the gastrointestinal tract
• Multi-flavor systems that reduce flavor fatigue
• Reduced aftertaste through selective sweetener and flavor combinations

Taste masking must not accelerate drug release. The best strategy is usually particle-level masking, where the barrier remains intact in the mouth but allows release under gastrointestinal conditions.

Sugar-reduced and sugar-free formulations

The presence of sucrose creates a clear product-line opportunity. A sugar-reduced or sugar-free Quillivant-type product could target:

• Families limiting dietary sugar
• Children with dental caries risk
• Patients requiring tighter carbohydrate management
• Institutional settings seeking standardized pediatric formulations
• Consumers who prefer non-sucrose products

Replacing sucrose is not a simple substitution. Sucrose contributes sweetness, solids, viscosity, mouthfeel, and overall vehicle structure. A replacement system may require a combination of polyols, bulking agents, high-intensity sweeteners, and rheology modifiers.

Candidate technologies include erythritol, maltitol, sorbitol, glycerin, allulose, sucralose, acesulfame potassium, and steviol glycosides. Each creates different risks involving osmolarity, gastrointestinal tolerance, taste profile, microbial control, and regulatory review.

Preservative reduction

Sodium benzoate is used to control microbial growth in the aqueous product. A preservative-reduced or preservative-free version could create a premium commercial position, but it would require an alternative microbial-control strategy.

Possible approaches include:

• Single-dose or unit-dose packaging
• Blow-fill-seal containers
• Low-water-activity vehicles
• Improved closure systems
• Alternative preservatives
• Aseptic manufacturing
• Shorter in-use periods supported by packaging controls

Quillivant XR is supplied as a reconstituted suspension with a defined in-use period. A formulation that extends the usable period after reconstitution would reduce pharmacy and caregiver waste. That benefit could support premium pricing if the product retains dose uniformity and microbiological quality.

What formulations are protected by Quillivant XR intellectual property?

Quillivant XR protection is likely to extend beyond the methylphenidate molecule. The commercial barrier may include claims directed to:

• Extended-release methylphenidate particles
• Coated or matrix-controlled particles
• Liquid suspension vehicles
• Particle-size distributions
• Release profiles
• Dose uniformity
• Reconstitution and storage conditions
• Methods of treating ADHD with the formulation

The key patent risk for a competing product is formulation overlap, not simply use of methylphenidate hydrochloride. A generic applicant may attempt to avoid infringement by changing polymer composition, particle size, coating thickness, buffer conditions, preservative system, or excipient concentrations. Those changes can create development and bioequivalence risks.

Public patent records have associated Quillivant XR with Tris Pharma formulation patents, including U.S. Patent No. 8,337,886. Patent scope and expiration must be assessed against the current FDA Orange Book listing, patent-term adjustment, pediatric extension, terminal disclaimers, and any later-listed patents. [2][3]

When does Quillivant XR lose exclusivity?

Quillivant XR received FDA approval in 2012. Its five-year new chemical entity exclusivity period would have ended in 2017 if the product received NCE treatment. That regulatory exclusivity is separate from patent protection. [1][4]

Exclusivity layer	Quillivant XR position
FDA approval	2012
NCE exclusivity	Typically five years from approval, subject to FDA classification
Orphan exclusivity	Not applicable based on the ADHD indication
Pediatric exclusivity	Depends on completed FDA-requested pediatric studies and applicable listing
Patent exclusivity	Depends on listed patents, expiration dates, term adjustments, and litigation
Formulation exclusivity	May arise from patent claims covering release technology and suspension design

The practical generic-entry date is therefore controlled by the latest enforceable patent or settlement restriction, not by the end of FDA exclusivity alone.

What is the Orange Book status of Quillivant XR?

The Orange Book is the controlling source for listed patents, patent-use codes, therapeutic-equivalence evaluations, and reference-product information. A generic applicant seeking approval before listed patent expiration may file an Abbreviated New Drug Application with a Paragraph IV certification. [2]

A Paragraph IV challenge would likely focus on one or more of the following:

1. Invalidity of formulation claims.
2. Noninfringement based on different particle coatings or excipients.
3. Lack of adequate written description or enablement.
4. Obviousness based on earlier methylphenidate suspension and extended-release technologies.
5. Failure of a listed patent to claim the proposed generic product.

Because Quillivant XR is a liquid extended-release suspension, an applicant must demonstrate pharmaceutical equivalence and bioequivalence while controlling particle settling, redispersion, dose withdrawal, and release kinetics. These technical requirements can make a Paragraph IV filing more expensive than a conventional immediate-release methylphenidate tablet.

Which companies are challenging Quillivant XR?

The competitive field includes generic methylphenidate manufacturers, specialty pediatric-drug developers, and stimulant companies with alternative liquid or chewable products. A complete company-by-company challenge assessment requires current Orange Book, FDA Paragraph IV, and federal court data.

The most relevant competitive products include:

Product	Active ingredient	Dosage form	Competitive distinction
Quillivant XR	Methylphenidate HCl	Extended-release suspension	Liquid, once daily, flexible dosing
Dyanavel XR	Amphetamine	Extended-release suspension	Liquid amphetamine alternative
Methylin oral solution	Methylphenidate HCl	Immediate-release solution	Lower technical barrier but shorter duration
Concerta	Methylphenidate HCl	Extended-release tablet	Long duration, requires swallowing
Jornay PM	Methylphenidate HCl	Delayed-release/extended-release capsule	Evening dosing and morning symptom control
Azstarys	Serdexmethylphenidate/d-methylphenidate	Capsule	Prodrug-based methylphenidate regimen

The main threat is not limited to a direct Quillivant XR generic. Liquid amphetamine products can substitute at the prescriber level, while chewables, capsules, and orally disintegrating products can compete for children with adherence or swallowing problems.

What commercial opportunities exist for Quillivant XR excipients?

Premium reformulation

A new formulation could preserve the existing extended-release profile while offering one or more of the following:

• Sugar-free or reduced-sugar vehicle
• Improved flavor and lower aftertaste
• Lower viscosity and easier syringe withdrawal
• Longer post-reconstitution stability
• Preservative-reduced packaging
• Smaller administration volume
• Refrigeration-free or temperature-tolerant storage
• Improved dose uniformity after limited shaking

Each change can support a separate lifecycle-management strategy, although patentability would depend on unexpected performance, defined composition ranges, or clinically meaningful advantages.

Pediatric adherence products

The strongest commercial opportunity is adherence improvement. Pediatric stimulant discontinuation frequently reflects taste, inconvenience, swallowing difficulty, duration mismatch, or caregiver administration problems. A formulation with better sensory acceptance and more reliable dosing can compete even after generic methylphenidate becomes available.

Hospital and institutional formulations

A unit-dose liquid presentation could target hospitals, residential facilities, schools, and specialty pharmacies. Unit-dose packaging would reduce contamination concerns and simplify administration records. The tradeoff is higher packaging cost and potentially lower retail flexibility.

International expansion

Excipient requirements differ by jurisdiction. A global product should assess:

• Acceptability of sodium benzoate and polysorbate 80
• Permitted color and flavor systems
• Sugar labeling requirements
• Pediatric excipient guidance
• Local limits for preservatives
• Stability under high-temperature and high-humidity conditions
• Country-specific requirements for controlled substances

A sugar-free, alcohol-free, allergen-controlled formulation could improve international positioning, although controlled-substance registration and distribution restrictions remain separate barriers.

How strong is the Quillivant XR patent estate?

The estate is technically stronger than a basic liquid methylphenidate formulation because the product combines active pharmaceutical ingredient, particle engineering, release control, suspension behavior, and dosing method. Its vulnerabilities arise from the maturity of methylphenidate science and the availability of prior art covering extended-release oral dosage forms.

Patent strength is highest where claims are tied to measurable product attributes, such as:

• Defined in vitro release windows
• Particle-size or coating parameters
• Specific suspension viscosity and redispersibility
• Demonstrated pharmacokinetic performance
• Narrow excipient ratios that produce unexpected stability

Broad claims covering methylphenidate in a liquid suspension are more vulnerable to invalidity and design-around strategies.

What manufacturing and IP barriers affect generic entry?

A generic manufacturer must solve several manufacturing problems:

• Reproducible drug-particle coating
• Narrow particle-size distribution
• Stable suspension during storage
• Rapid and complete redispersion
• Accurate syringe dosing
• Consistent release after reconstitution
• Microbiological control
• Robust filling and reconstitution processes

The key manufacturing barrier is scale-up. A laboratory formulation may meet dissolution specifications while failing at commercial scale because coating uniformity, mixing energy, or suspension structure changes with batch size.

Excipient suppliers with proprietary polymer grades, flavor systems, or suspension platforms could capture value by licensing know-how rather than selling commodity ingredients. The most defensible position would combine an excipient composition with process parameters and performance data.

What revenue exposure does Quillivant XR create?

Tris Pharma is a private company, and publicly available financial disclosures do not generally isolate Quillivant XR revenue. Revenue exposure should therefore be assessed through prescription volume, net price, payer coverage, product switching, and duration of patent protection rather than through a separately reported product segment.

Key commercial risks include:

• Generic entry into methylphenidate liquid products
• Substitution by liquid amphetamine products
• Payer pressure on branded stimulants
• Seasonal prescription patterns
• Supply interruptions for controlled-substance products
• Caregiver preference for capsules, chewables, or patches
• Formulation changes that reduce taste acceptance or dose reliability

A reformulation with a clear adherence or administration benefit could defend share after base-product patent expiry, but only if the improvement is visible to prescribers, caregivers, and payers.

Key Takeaways

• Quillivant XR is a once-daily extended-release methylphenidate oral suspension.
• Its excipient system supports sweetness, suspension stability, wetting, buffering, preservation, and pediatric taste acceptance.
• The leading lifecycle opportunity is a sugar-free or reduced-sugar formulation with equivalent pharmacokinetics.
• Other attractive opportunities include improved taste masking, lower viscosity, longer in-use stability, unit-dose packaging, and preservative reduction.
• Generic competition must address particle engineering, release control, suspension uniformity, and microbial stability.
• The relevant IP barrier is likely formulation and manufacturing technology, not methylphenidate itself.
• FDA exclusivity and patent protection are separate. The Orange Book and current litigation record control the practical entry analysis.
• Quillivant XR revenue is not separately disclosed in public company reporting, so exposure should be modeled through market share, pricing, payer access, and entry timing.

FAQs

Can sucrose be removed from Quillivant XR without changing the drug release profile?

Yes, but sucrose replacement would require reformulation of sweetness, bulk, viscosity, mouthfeel, osmolarity, and suspension behavior. The replacement vehicle must preserve dose uniformity and pharmacokinetics.

Is sodium benzoate necessary in a Quillivant-type suspension?

It is used for microbial preservation, but alternative approaches may include different preservatives, unit-dose packaging, aseptic processing, or lower-water-activity systems. Each approach requires microbiological and stability validation.

Could a generic Quillivant XR use different flavors?

Yes. Flavoring is generally a design-around opportunity, but the generic must still meet pharmaceutical equivalence, bioequivalence, stability, and labeling requirements. Flavor changes do not by themselves avoid patents covering the underlying release technology.

Is Quillivant XR more difficult to copy than immediate-release methylphenidate solution?

Yes. An extended-release suspension requires control of drug-particle properties, release kinetics, redispersion, viscosity, dose withdrawal, and reconstitution stability. Immediate-release solution products generally present fewer formulation barriers.

What is the most valuable excipient innovation for Quillivant XR?

A low-viscosity, sugar-free suspension vehicle that improves taste, reduces shaking and syringe-withdrawal difficulty, and preserves the existing pharmacokinetic profile offers the clearest commercial opportunity.

References

1. U.S. Food and Drug Administration. (2024). Quillivant XR prescribing information. Tris Pharma, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. United States Patent and Trademark Office. (2012). U.S. Patent No. 8,337,886: Liquid formulations of methylphenidate. USPTO.

4. U.S. Food and Drug Administration. (2024). New chemical entity exclusivity and generic drug approval pathways. FDA.